Nilotinib 200 mg (Generic)

Nilotinib 200 mg (Generic) is an oral anticancer medication belonging to the class of tyrosine kinase inhibitors (TKIs). It is primarily prescribed for the treatment of Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic and accelerated phases in adult and pediatric patients.

Nilotinib works by specifically targeting and inhibiting the BCR-ABL tyrosine kinase enzyme, which is responsible for the uncontrolled growth of abnormal white blood cells in CML. By blocking this abnormal signaling pathway, the medicine helps slow disease progression, reduce leukemic cell proliferation, and improve long-term patient outcomes.

Key Features & Benefits:

• Used for Ph+ CML in both newly diagnosed and previously treated patients.

• Helps prevent progression of leukemia to advanced or blast crisis phases.

• Available in 200 mg oral capsule form for convenient administration.

• Generic formulation ensures cost-effectiveness without compromising therapeutic efficacy.

Dosage & Administration:

• Typically administered orally twice daily (approximately 12 hours apart) on an empty stomach or at least 2 hours after a meal.

• Should be taken under the guidance and monitoring of a qualified oncologist.

Safety Information:

• Common side effects may include nausea, rash, headache, fatigue, muscle pain, or low blood counts.

• Regular monitoring of blood counts, liver function, and ECG is recommended during therapy.

• Contraindicated in patients with hypersensitivity to Nilotinib or its components.